Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | GOT1 | P17174 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SCD | O00767 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7557692 | 0.91 | ENPP2 (0.46) | SLC2A1PTPN1PPARGENPP2MEN1 | |
| SCHEMBL7553259 | 0.89 | PTPN1 (0.45) | SLC2A1PTPN1ENPP2MEN1KMT2A | |
| SCHEMBL7556297 | 0.89 | SLC2A1 (0.44) | SLC2A1PTPN1PPARGMEN1KMT2A | |
| SCHEMBL7556493 | 0.88 | PPARG (0.42) | SLC2A1PTPN1PPARGALOX5MEN1 | |
| SCHEMBL7556649 | 0.86 | MAOB (0.39) | SLC2A1PTPN1PPARGALOX5ENPP2 | |
| SCHEMBL7559213 | 0.84 | PTPN1 (0.40) | PTPN1PPARGALOX5ENPP2MEN1 | |
| SCHEMBL5470542 | 0.82 | PTPN1 (0.48) | PTPN1PPARGMEN1KMT2AHTT | |
| SCHEMBL5470545 | 0.82 | PTPN1 (0.48) | PTPN1PPARGMEN1KMT2AHTT | |
| SCHEMBL7554795 | 0.81 | ACHE (0.47) | PTPN1PPARGALOX5MEN1KMT2A | |
| SCHEMBL7559696 | 0.81 | AMY1A (0.52) | MEN1KMT2AMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020115700-A1 | Substituted indole compounds and methods of their use | CHIN ALLISON C (US) | 2002-08-22 | — | — | US | disclosed |
| US-6372742-B1 | TELOMERASE ENZYME INHIBITORS AND ANTICANCER AGENTS | GERON CORPORATION | 2002-04-16 | — | — | US | disclosed |
| EP-1109808-A1 | SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | Geron Corporation (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2001002394-A1 | SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | GERON CORPORATION (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115700-A1 | Substituted indole compounds and methods of their use | TERT, INMT, POT1 | SLC2A1 4766/4885PTPN1 3030/4885PPARG 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.